Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Labwire Inc. -- Ignore unavailable to you. Want to Upgrade?

To: rogerover who wrote (1402)	1/5/2009 1:28:58 PM
From: Sidney Reilly	1 Recommendation Read Replies (2) \| Respond to of 1698

From the original post... Share Structure per T.A. - November 25, 2008 Authorized Shares: 200,000,000 Outstanding Shares: 142,699,001 Restricted Shares: 124,149,002 (120 MM Mgmt 144's) Floating Shares: 18,549,998 It's hard to estimate revenue from contracts or margins. No shares will be sold to fund operations or expansion. They are handling that with loans. The unissued shares are for acquisitions. And Labwire will uplist to the BB very soon. IMO at the current pps this is a multi-bagger. Do your own DD before making investment decisions.

To: rogerover who wrote (1402)	1/5/2009 2:09:43 PM
From: scion	Read Replies (1) \| Respond to of 1698

We intend to raise additional capital through an offering of our Common Stock or other securities to provide additional working capital to fund the expansion of operations through acquisitions and the addition of new clients through marketing efforts and joint ventures with other service organizations. We intend to seek up to approximately $2.0 million in capital in the near future in this connection. The exact amount of funds raised, if any, will determine how aggressively we can grow and what additional projects we will be able to undertake. Assuming that we are able to raise the $2.0 million in new capital, we currently anticipate spending approximately $250,000 in marketing and sales in its efforts to sign new clients and seek additional alliances. No assurance can be given that we will be able to raise additional capital, when needed or at all, or that such capital, if available, will be on terms acceptable to us. If adequate funds are not available on acceptable terms, our business, results of operations and financial condition could be materially adversely affected. In a worst-case scenario, we would have to scale back or cease operations, and we might not be able to remain a viable entity. In addition common stock may also be issued for conversion or settlement of debt and/or payables for equity, future obligations which may be satisfied by the issuance of common shares, and other transactions and agreements which may in the future result in the issuance of additional common shares. The common shares that we may issue in the future could significantly increase the number of shares outstanding and could be extremely dilutive. sec.gov